SAM Chun Dang Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SAM Chun Dang Pharm makes prescription medicines, including antibiotics, cardiovascular treatments, digestive-disease drugs, and eye drops, supplied to hospitals and pharmacies in South Korea.
It is listed on KOSDAQ, South Korea's tech and small-cap exchange. The company operates through subsidiaries that manufacture ophthalmic preparations and support export approvals in North America and Japan, making its eye-care and international operations a distinct part of its business alongside the core domestic prescription-drug line.
Summary is AI-generated and may contain errors · figures from DART filings
Its subsidiary Optus Pharm specialises in eye-drop and ophthalmic drug manufacturing, while SCD US, INC and SCD BIOTECH, LLC handle product certification and approvals for North American exports.
SAM Chun Dang Pharm in five facts
What does SAM Chun Dang Pharm do?
SAM Chun Dang Pharm makes prescription medicines, including antibiotics, cardiovascular treatments, digestive-disease drugs, and eye drops, supplied to hospitals and pharmacies in South Korea.
Where is SAM Chun Dang Pharm listed and in which sector?
SAM Chun Dang Pharm (Korean name: 삼천당제약) trades under KRX code 000250 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is SAM Chun Dang Pharm?
Its market capitalisation was US$3.8B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SAM Chun Dang Pharm's latest annual revenue and operating profit?
For fiscal year 2025, SAM Chun Dang Pharm reported revenue of US$175M, operating profit of US$6.4M and net income of US$9.1M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was up 9.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 20
- [Amended] Half-year report (2026.06)Oct 8
- [Amended] Quarterly report (2026.03)Oct 8
- [Amended] Disclosure
Sam Chun Dang Pharm amended its earlier disclosure on the exclusive Canada distribution deal with Apotex (worth up to USD 15,000,000) for its aflibercept biosimilar SCD411, adding that a new macular-degeneration product has also been added to the Canada and six-Middle-East-country agreements, with a related termination-fee clause and an extended disclosure deferral deadline of October 1, 2036.
Supply contract · Oct 1 - [Amended] DisclosureSupply contract · Feb 19
- Cash/in-kind dividend decision
SAM Chun Dang Pharm declared a cash dividend of US$0.03 per share.
Dividend · Feb 10 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SAM Chun Dang Pharm reported consolidated results for FY2025: revenue of US$159M (+9.9% year on year), operating profit of US$5.81M (+220.5% year on year) and net income of US$8.16M (from a loss a year earlier).
Earnings · Feb 10